Anti igf ir

Manufactured by Santa Cruz Biotechnology

Sourced in United States

Anti-IGF-IR is a laboratory reagent used for the detection and quantification of Insulin-like Growth Factor I Receptor (IGF-IR) in various samples. It is a specific antibody designed to bind to the IGF-IR protein, allowing researchers to measure its expression levels or study its role in biological processes.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

IGF-IR) (2 citations) Rabbit-anti-IGF-IR (2 citations) Mouse anti-IGF-IR antibody (1 citations)

3 protocols using anti igf ir

IGF-I Signaling Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Subconfluent cells were lysed and subjected to western blot analysis, as previously described [28 (link)]. To evaluate IGF-I-dependent activation of downstream signaling after DDR1 silencing or overexpression, cells were serum-starved for 24 h, and then stimulated with IGF-I (10 nM) for 5 min. The following antibodies were used: anti-DDR1, anti-IGF-IR and anti-β-tubulin (Santa Cruz Biotechnology); anti-P-IR/P-IGF-IR (Y1150/Y1151), anti-IGF-IR, anti-P-Akt (S473), anti-AKT, anti-P-ERK1/2 (T202/Y204), anti-ERK1/2, anti-P-DDR1 Tyr792 (Cell Signaling Technology); anti-P-DDR1 Tyr513 (Origene); anti-β-actin (Sigma Aldrich); anti-phosphotyrosine antibody (4G10) (Upstate, Biotechnology).

Malaguarnera R., Nicolosi M.L., Sacco A., Morcavallo A., Vella V., Voci C., Spatuzza M., Xu S.Q., Iozzo R.V., Vigneri R., Morrione A, & Belfiore A. (2015). Novel cross-talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses. Oncotarget, 6(18), 16084-16105.

+ Open protocol

+ Expand

Investigating IGF-I and TGF-β2 Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human insulin-like growth factor I (IGF-I; 291-G1; 10 ng/ml) and transforming growth factor-β2 (TGF-β2; 302-B2-010; 10 ng/ml) were obtained from R&D Systems. A selective inhibitor of ERK1/2 (U0126; 10 μM; Cell Signaling Technology, Inc.) and allosteric inhibitor of IGF-IR (AG1024; 1 µM; Sigma-Aldrich; Merck KGaA) were used in the present study for 1 h. Primary antibodies from Santa Cruz Biotechnology, Inc. were used, and these included anti-lumican (sc166871; mouse monoclonal; 1/100 dilution for western blot analysis or 1/50 for immunofluorescence), anti-β-catenin (sc7963; mouse monoclonal; 1/300 dilution), anti-ERK1/2 (sc514302; mouse monoclonal; 1/200 dilution), anti-IGF-IR (sc81464; mouse monoclonal; 1/100 dilution), anti-pERK1/2 (sc136521; mouse monoclonal; 1/100 dilution), anti-Smad2 (sc6200; goat polyclonal; 1/200 dilution) and anti-pSmad2 (sc101801; rabbit polyclonal; 1/200 dilution). In addition, anti-actin (MAB1501; mouse monoclonal; 1/5,000 dilution; EMD Millipore), anti-p-IGF-IR (PA5-37602; polyclonal rabbit; 1/500 dilution; Thermo Fisher Scientific, Inc.), keratan sulfate (KS; 270427; mouse monoclonal; 1/1,000 dilution; Seikagaku Corporation) and keratanase II (100812; 0,005 µ/ml; Seikagaku Corporation) were utilized. Secondary-HRP antibodies anti-rabbit (AP182PR) and anti-mouse (AP192PM) were used at a 1/5,000 dilution and obtained from Millipore.

Papoutsidakis A., Giatagana E.M., Berdiaki A., Spyridaki I., Spandidos D.A., Tsatsakis A., Tzanakakis G.N, & Nikitovic D. (2020). Lumican mediates HTB94 chondrosarcoma cell growth via an IGF-IR/Erk1/2 axis. International Journal of Oncology, 57(3), 791-803.

+ Open protocol

+ Expand

Klotho and IGF-IR Signaling Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were lysated and total protein was extracted. Western blot was performed as previously described [17 (link)]. Anti-Klotho, anti-p-IGF-IR, anti-IGF-IR, anti-p-AKT1, and anti-GAPDH antibodies were purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA). Anti-AKT antibody, anti-p-PI3K, and anti-p-mTOR antibodies were purchased from Cell Signaling Technology (Danvers, MA, US).

Xie B., Cao K., Li J., Chen J., Tang J., Chen X., Xia K., Zhou X., Cheng Y., Zhou J, & Xie H. (2016). Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma cells by activating NF-κB. Oncotarget, 7(49), 80765-80782.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!